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ABSTRACT 
 
 
 How the TCR repertoire, together with risk-associated major histocompatibility 
complex (MHC), imposes susceptibility for autoimmune disease is not fully understood. 
A small fraction of TCR α or β chains are “public”, and are shared by most individuals. 
High-throughput sequencing of the mouse TCRβ repertoire during myelin 
oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune 
encephalomyelitis (EAE) identified a public TCRβ chain, TCRβ1, which was highly 
shared among individual mice and preferentially deployed during EAE. Retrogenic 
expression of TCRβ1 resulted in spontaneous early-onset EAE in mice with high 
penetrance and severity, despite being paired with a diverse endogenous TCRα repertoire. 
To further study autoimmunity conferred by this highly reactive beta chain, we generated 
TCRβ1 transgenic mice. Unexpectedly, TCRβ1 transgenic mice failed to develop 
spontaneous disease and were also resistant to standard EAE induction by MOG 
immunization. Despite the absence of disease, ~5% of TCRβ1 transgenic CD4+ T cells 
from unimmunized mice were MOG-specific, and these further expanded in response to 
MOG immunization. Three independent transfer models, including transfer of in vitro 
activated TCRβ1 splenocytes, transfer of TCRβ1 bone marrow, and a mock retrogenic 
system, all resulted in EAE in recipient mice, indicating there is no T cell-intrinsic 
blockade to pathogenesis. MOG-responsive transgenic T cells also expressed higher 
levels of PD-1 and Lag3 in comparison to those from WT and 2D2 mice, suggesting that 
they might be more prone to exhaustion. TCRβ1 transgenic T cells secreted higher levels 
of inflammatory cytokines IFN-γ and IL-17 relative to WT T cells, however these levels 
were comparable to those in pathogenic 2D2 MOG-responsive T cells. These results 
suggest that tolerance mechanisms in TCRβ1 transgenic mice prevent T cell 
pathogenicity and disease. Further studies are needed to fully resolve the mechanisms 
responsible for protection.   
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CHAPTER 1.    INTRODUCTION 
 
 
Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis 
 
Multiple sclerosis (MS) is one of the most widespread chronic inflammatory 
diseases of the central nervous system (CNS). An estimated 2.3 million people worldwide 
have MS, including 250,000-350,000 patients in the US. MS is characterized by T-cell 
mediated autoimmune demyelination and axonal damage [1, 2]. MS is a potentially 
disabling disease, with patients showing variable symptoms such as fatigue, difficulty in 
walking, and muscle weakness or rigidity [1-3]. In the 150 years since the discovery of 
MS, the exact cause and nature of the disease remains unclear, and no curative FDA 
approved medications for MS are currently available [3, 4].  
 
Experimental autoimmune encephalomyelitis (EAE) is an animal model of T-cell 
mediated autoimmune demyelination characterized by T cell and monocyte infiltration in 
the CNS. Due to similarities in their key pathological features, EAE is a common animal 
model for pre-clinical studies of MS [5-8]. There are two common methods for inducing 
EAE in mice: passive and active EAE induction. Passive EAE induction involves 
adoptive transfer of encephalitogenic cells into naïve mice [5-8]. Active EAE induction 
requires immunization with myelin antigens emulsified in complete Freund’s adjuvant 
(CFA) and co-administration of pertussis toxin. Frequently used myelin autoantigens 
include myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and 
proteolipid protein (PLP) [5-9]. MOG is a 28 kDa glycoprotein that accounts for about 
0.1% of total CNS myelin [10]. It was first identified as a key autoantigen involved in the 
autoimmune demyelination response in EAE by immunizing guinea pig with CNS 
homogenates in complete Freund’s adjuvant[11]. Immunization with the MOG35-55 
peptide can induce EAE in C57BL/6J mice [12]. 
 
 
Public T Cell Receptor and TCRβ1 
 
T cell-mediated autoimmunity is dependent on T cell receptor (TCR) recognition 
of antigenic peptides presented in the context of the major histocompatibility complex 
(MHC) protein. T cells mature in the thymus, and their survival is dependent on 
productive recombination of TCR α and β chains that form a heterodimer. Somatic 
recombination of V (variable), D (diversity) and J (junction) gene segments form the 
TCR variable domain, and random addition and deletion of nucleotides at the junctions 
results in a unique sequence. This process of somatic recombination followed by the 
pairing of individually recombined α and β chains generates highly unique TCR 
sequences that recognize a diverse array of potential pathogens [13, 14]. 
 
Theoretically, the TCR repertoire should be unique among individuals, as there 
are more potential TCR sequences than there are T cells circulating at any given time. 
However, due to biases in the recombination process, a small fraction of TCR α and β 
chains are preferentially formed and are shared by most individuals [13, 14]. These 
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shared, or “public”, TCRs have been preferentially associated with autoimmune diseases, 
including MS and EAE [15-17]. Our lab previously performed high-throughput 
sequencing of the TCRβ repertoire of mice with MOG-induced EAE. We identified a 
public TCRβ chain, TCRβ1, which was highly shared among individual mice and 
preferentially enriched during EAE [18]. Bone marrow cells from TCRβ-/- mice were 
transduced with TCRβ1 to generate retrogenic mice. Retrogenic expression of TCRβ1 
resulted in spontaneous early-onset EAE in mice, despite being paired with a diverse 
endogenous TCRα repertoire. This indicated that this single, highly public TCRβ chain 
was sufficient to confer TCRαβ MOG-reactivity and disease [19]. 
 
 
TCRβ1 Transgenic Mice Are Resistant to EAE 
 
To further study autoimmunity conferred by this highly reactive TCRβ chain, we 
generated TCRβ1 transgenic mice. We hypothesized that TCRβ1 transgenic mice would 
be a more imitative, spontaneous mouse model for MS, compared to the immunization 
and cell transfer models of EAE. TCRβ1 retrogenic mice succumbed to spontaneous and 
severe EAE by approximately 8 weeks after bone marrow transfer [19]. We monitored 
TCRβ1 transgenic mice for symptoms of EAE or other autoimmune disease for 6 months. 
No spontaneous neuropathology was observed and further histological analysis did not 
reveal signs of EAE or other autoimmune disorders such as inflammatory bowel disease, 
colitis, or immune cell infiltration of other tissues. To determine if immunization could 
induce disease, similar to wild type B6 mice, we immunized TCRβ1 transgenic and wild 
type mice with MOG35-55 to induce EAE. Surprisingly, TCRβ1 mice were completely 
resistant to standard induction of EAE by immunization (Figure 1-1).  This difference in 
phenotype between TCRβ1 retrogenic and transgenic mice presents an opportunity to 
study the determinants of T cell pathogenicity during EAE, and may provide insights into 
mechanisms of tolerance and disease induction in EAE. 
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Figure 1-1. TCRβ1 transgenic mice are resistant to standard EAE immunization 
WT (B6) and TCRβ1 transgenic mice were immunized with MOG35-55 peptide in CFA 
(s.c.) and pertussis toxin (i.p.) and monitored for signs of disease. Clinical scoring was: 1, 
limp tail; 2, hind limb paresis or partial paralysis; 3, total hind limb paralysis; 4, hind 
limb paralysis and body or front limb paresis or paralysis; and 5, moribund. 
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CHAPTER 2.    METHODOLOGY 
 
 
Mice 
 
B6 [C57BL/6J (B6)], TCRβ-/- [B6.129P2-Tcrbtm1Mom/J (TCRβ-/-)], and 2D2 
[C57BL/6-Tg (Tcra2D2, Tcrb2D2)1Kuch/J] mice [20] were purchased from The Jackson 
Laboratory (Bar Harbor, ME). TCRβ1 mice were generated in the transgenic core facility 
at St. Jude Children’s Research Hospital. Mice were housed under specific pathogen-free 
conditions and animal experiments were carried out in compliance with the guidelines of 
the Institutional Animal Care Committee at St. Jude Children’s Research Hospital. 
Animal care was provided in Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) accredited animal barrier facilities at St. Jude 
Children’s Research Hospital. 
 
 
TCRβ1 Transgenic Mice and Genotyping 
 
TCRβ1 was cloned in phCD2-VA vector using EcoRI and SnaBI sites. This 
TCRβ is driven under CD2 promoter. The vector was linearized by KpnI and NotI 
restriction sites to remove vector backbone. 
 
Several pl of 2 ng/μl DNA of the linearized DNA construct was injected into the 
pronucleus of C57BL/6 zygotes. Approximately 25 injected zygotes were transferred into 
an infundibulum of a 0.5 dpc (days postcoitum) pseudo pregnant CD-1 foster mother and 
carried to term. TCRβ1 mice were first generated in the transgenic core facility on a 
B10.BR background. They were crossed onto a TCRβ-/- background, and finally onto a 
B6 background, to generate TCRβ1 without endogenous TCRβ on a B6 background.  
 
To genotype TCRβ1 transgenic mice, PCR screening of genomic DNA was done 
with the following primers: (5’ – CTCGAGTTGGCTACCCCCTCTCA – 3’ and 5’ – 
CGTAGAATTTTTTTTCTTGACCATGG – 3’). In other cases, flow cytometric analysis 
of Vβ8 staining of blood from mice was used to determine genotype. 
 
 
Flow Cytometry 
 
Red blood cells were lysed with ACK lysis buffer prior to staining. Fc receptors 
were blocked with FcR blocking reagent (Miltenyi Biotec, San Diego, CA). Cell surface 
staining was performed for 20 min at 4°C in PBS containing 0.1% sodium azide and 2% 
(vol/vol) fetal bovine serum (FBS). Monoclonal antibodies (Ab) specific for CD4 (clone 
RM4-5), CD8 (clone 53-6.7), TCRβ (clone H57-597), CD3 (clone 17A2), CD25 (clone 
PC61), or CD69 (clone H1-2F3) were purchased from BD Biosciences (San Jose, CA). 
The fluorochrome conjugation for each antibody was variable between experiments, but 
the clone number was consistent. For intracellular Foxp3 staining, cells were first stained 
with surface markers, fixed, permeabilized with the Foxp3 Staining Buffer Set 
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(eBioscience, San Diego, CA), and stained for intracellular Foxp3 (clone FJK-16s). Flow 
cytometric analysis was performed on an LSRFortessa (BD Biosciences) and analyzed 
with FlowJo software (Tree Star, Ashland, OR). 
 
 
EAE Immunization 
 
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) was synthesized by St. 
Jude Hartwell Center for Biotechnology and HPLC purified prior to use. Each mouse was 
s.c. (subcutaneous) immunized with 100 μg MOG35–55 peptide emulsified in complete 
Freund's adjuvant (Difco, Detroit, MI) containing 0.4 mg heat-killed Mycobacterium 
tuberculosis H37RA (Difco). Two hundred ng of pertussis toxin (List Biological 
Laboratories, Campbell, CA) was administered i.p. (intraperitoneal) on day 0 and day 2. 
Clinical scoring was as follows: 1, limp tail; 2, hind limb paresis or partial paralysis; 3, 
total hind limb paralysis; 4, hind limb paralysis and body or front limb paresis or 
paralysis; 5, moribund or deceased. 
 
 
Adoptive EAE Transfer 
 
Donor mice were immunized s.c. with 100 μg MOG35–55 peptide emulsified in 
complete Freund's adjuvant (Difco, Detroit, MI) containing 0.4 mg Mycobacterium 
tuberculosis H37RA (Difco). Spleens from immunized mice were extracted 10 days later 
and processed through a 40 μm filter (FalconTM) to obtain a single cell suspension. Cells 
were incubated with ACK lysis buffer (Quality Biological) for 3-4 minutes at room 
temperature and buffer was neutralized with 10 ml of PBS with 2% FBS. After 
centrifugation at 1500 RPM for 5 minutes, cells were cultured in presence of MOG35–55 
(100 μg/ml), IL-6 (20 ng/ml), and IL-23 (20 ng/ml) in a concentration of 3.5-4 × 106 
cells/ml. After 5 days, 5 × 106 cultured cells/mouse were injected i.v. (intravenous) into 
8-12 week old irradiated (450 rad) TCRβ-/- recipient mice to induce adoptive EAE. All 
cytokines were obtained from Peprotech. 
 
 
Generation of Mock Retrogenic and Retrogenic Mice 
 
Murine stem cell virus (MSCV)-GFP and MSCV-TCRβ1-GFP retroviral vectors, 
in which the GFP is linked through an IRES to generate a polycistronic construct, were 
used to generate GPE86 viral producer cell lines. (MSCV)-GFP viral supernatants and 
MSCV- TCRβ1-GFP viral supernatants were used to transduce hematopoietic progenitor 
cells (HPCs) from TCRβ1 transgenic mice and TCRβ-/- mice respectively as described 
previously [21, 22]. Bone marrow transduced with MSCV virus were used to generate 
mock retrogenic mice. Bone marrow transduced with MSCV-TCRβ1 virus were used to 
generate retrogenic mice. Transduced bone marrow cells (~2 × 106 per mouse) were 
injected via the tail vein into irradiated TCRβ-/- (450 rad) recipient mice. Transduction 
efficiency (around 40%) was confirmed by flow cytometry for GFP expression. 
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Cell Proliferation Assays 
 
Spleens were isolated from TCRβ1, WT B6, or 2D2 mice. Red blood cells were 
lysed with ACK lysis buffer and splenocytes were cultured at 1 × 105 cells per well in 96-
well plates in the presence of 2 μg/ml soluble anti-CD28 (BD Biosciences) and 
stimulated with 100 μg/mL MOG35-55 peptide for 72 hr. For 3H thymidine incorporation, 
plates were pulsed with 1 μCi/well 3H thymidine (PerkinElmer, Boston, MA) and 
incubated for another 8 hr before scintillation counting. The proliferative response was 
measured as the 3H thymidine incorporation expressed as mean C.P.M (counts per 
minute) of triplicate cultures. For quantitative assessment of proliferation, the CellTrace 
Violet Cell Proliferation kit (Invitrogen) was used according to the manufactory’s 
instruction. Cells were labeled with 5 μM CellTrace violet dye for 7 min at 37°C in dark 
and cultured with indicated stimuli for 72 hr. Cells were then stained with surface 
markers, and proliferation was measured by cell trace violet dye dilution by flow 
cytometry. For positive and negative controls in these experiments, cells were stimulated 
with plate bound 3 μg/ml anti-CD3, or given no stimulation, respectively. 
 
 
Cytokine Analysis 
 
Cultures were prepared as in cell proliferation assays, and culture supernatants 
were collected after 72 hr and analyzed for IL-2, IL-4, IL-10, IFN-γ, and IL-17A by using 
Milliplex MAP mouse cytokine immunoassay kit (Millipore, Billerica, MA) on a 
Luminex (Bio-Rad) instrument. 
 
 
Statistics 
 
Means and standard error of the mean (SEM) were calculated in PRISM software 
(GraphPad, La Jolla, CA). Plots demonstrate mean ± 1 SEM. Two-tailed Student’s t-test 
was applied to compare between two groups. One-way ANOVA was applied for multiple 
groups. A value of p < 0.05 was considered statistically significant.  
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CHAPTER 3.    RESULTS 
 
 
TCRβ1 Transgenic Mice Have Abnormal Treg Compartment 
 
 Standard induction of EAE with MOG35-55/CFA emulsion failed to cause EAE in 
TCRβ1 transgenic mice. Normal T cell compartments are essential to immune response 
to antigens and abnormal T cell compartments may cause failure of an expected response 
to MOG35-55 in TCRβ1 transgenic mice. 
 
 Thus we first characterized the major T cell compartments in the spleen and 
lymph nodes of TCRβ1 transgenic mice to determine if an abnormal composition of T 
cell subsets may influence susceptibility to disease. TCRβ1 mice have normal 
percentages of CD4+ and CD8+ T cells in both organs relative to WT B6 mice  
(Figure 3-1). Moreover, the numbers of CD4+ and CD8+ T cells in spleens of TCRβ1 
mice are comparable to WT B6 mice (Figure 3-1). The percent of Foxp3+ regulatory T 
cells (Treg) in TCRβ1 mice was reduced by 50% in both spleen and lymph nodes, 
relative to WT B6 mice (Figure 3-1). The absolute number of Foxp3+ regulatory T cells 
(Treg) was also reduced in spleens of TCRβ1 mice in comparison to WT B6 mice 
(Figure 3-1). 
 
 
TCRβ1 Transgenic Mice Have MOG-reactive T Cells 
 
 TCRβ1 retrogenic mice had high numbers of MOG-reactive T cells and develop 
spontaneous early-onset EAE [19]. However, TCRβ1 transgenic mice did not develop 
spontaneous EAE and further failed to develop disease upon active induction with 
MOG35-55/CFA emulsion. It is possible that MOG-reactive T cells are deleted during T 
cell maturation, before they reach the peripheral lymphoid organs, and a lack of MOG-
reactive T cells in vivo may lead to inability of TCRβ1 transgenic mice to develop EAE. 
Thus, we next asked if TCRβ1 transgenic mice have endogenous MOG-reactive T cells.  
 
Splenocytes were harvested from unimmunized TCRβ1 transgenic mice and 
stimulated with MOG peptide in vitro, and 3H-thymidine incorporation was used as a 
readout of proliferation. Upon stimulation with MOG, TCRβ1 transgenic T cells 
proliferated in a dose dependent manor (Figure 3-2a). This result was confirmed using a 
CellTrace violet proliferation assay, and it was calculated that approximately 5% of the 
initial CD4+ population was proliferating in response to MOG (Figure 3-2b, c). We also 
observed a population of CD8+ TCRβ1 T cells that proliferate in response to MOG 
stimulation (Figure 3-2d). Splenocytes from MOG-immunized TCRβ1 transgenic mice 
also proliferated in response to MOG, with greater numbers (around 12% of input CD4+ 
T cells) proliferating upon MOG stimulation than unimmunized mice. These results 
indicate that MOG-reactive T cells were present, and activated and expanded upon MOG 
immunization (Figure 3-3). The proliferation assays confirm the existence of antigen-
responsive cells in TCRβ1 mice, and resistance to EAE induction is not due to lack of 
MOG-reactive T cells.  
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Figure 3-1. Reduced Treg in spleen and lymph nodes of TCRβ1 transgenic mice 
Spleen and lymph nodes from naïve TCRβ1 or WT (B6) mice were harvested, and 
analyzed with flow cytometry. Upper panels show percentages of CD4+ T cells, CD8+ T 
cells, and CD4+Foxp3+ T cells (Treg) in spleen and lymph nodes. Plots shown results 
from individual mice (dots) and mean values (bars). Lower panels display absolute 
numbers of CD4+ T cells, CD8+ T cells, and CD4+Foxp3+ T cells (Treg) in spleen. 
(*p<0.05, ***p<0.001, ****p<0.0001). 
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Figure 3-2. TCRβ1 transgenic mice have MOG-specific T cells 
(a) Splenocytes from naïve TCRβ1 or WT (B6) mice were stimulated with MOG35-55 (100 
μg/ml) or αCD3 for 72hr. Proliferation was monitored by on day 3 by 3H-thymidine 
incorporation. (b-d) Splenocytes from TCRβ1 or WT mice were labeled with CellTrace 
Violet and stimulated with MOG35-55 (100 μg/ml) or αCD3 for 72 hr. (b) Proliferation of 
CD4+ T cells as monitored by CellTrace Violet dilution. (c) The percent of the initial 
CD4+ T cell population undergoing division was calculated by dividing each division 
peak by 2n, where n=division number, to estimate initial cell numbers forming each peak. 
(d) Proliferation of CD8+ T cells as monitored by CellTrace Violet dilution. 
(****p<0.0001). 
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Figure 3-3. TCRβ1 transgenic T cells are MOG-specific and further expand in 
response to MOG immunization 
(a) TCRβ1 and WT mice were immunized with MOG35-55 peptide. Splenocytes were 
isolated 10 days later and stimulated with MOG35-55 (100 μg/ml) or αCD3 for 72 hr. 
Proliferation was monitored on Day 3 by 3H-thymidine incorporation. (b-c) Splenocytes 
from immunized TCRβ1 or WT mice were labeled with CellTrace Violet and stimulated 
with MOG35-55 (100 μg/ml) or αCD3 for 72 hr. (b) Proliferation of CD4+ T cells was 
monitored by CellTrace Violet dilution and (c) the percent of the initial CD4+ T cell 
population undergoing division was calculated. The percent of initial cells dividing in 
response to indicated stimulus was calculated by dividing each division peak by 2n, where 
n=division number, to estimate initial cell numbers forming each peak. (**p<0.01). 
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TCRβ1 Cells Are Able to Mediate EAE Disease 
 
 T cells originate from hematopoietic stem cells in the bone marrow. The 
lymphoid progenitors of these cells migrate to the thymus to become mature functional T 
cells. The matured T cells then exit the thymus and circulate in the periphery. Abnormal 
T cell development may leave T cells in TCRβ1 transgenic mice intrinsically unable to 
become pathogenic cells and cause EAE in mice. Thus we next asked if TCRβ1 T cells 
can be manipulated to make them pathogenic, or if they are intrinsically unable to cause 
disease.  
 
We utilized three separate methods to investigate this. First, bone marrow was 
transferred directly from TCRβ1 transgenic mice into sub-lethally irradiated TCRβ-/- mice 
and disease progression was monitored. Recipient mice exhibited mild EAE symptoms, 
indicating that TCRβ1 bone marrow can produce pathogenic T cells under these 
conditions (Figure 3-4a). Although a WT bone marrow transfer control was not present 
in the experiment shown, EAE symptoms do not develop after transfer of WT bone 
marrow into irradiated mice. 
 
 Second, we asked if mature TCRβ1 T cells from transgenic mice can become 
pathogenic after culture in conditions that have been shown to increase EAE 
pathogenicity. Stimulation of MOG reactive T cells with MOG peptide, IL-6 and IL-23 
has been shown to generate encephalitogenic T cells that cause disease in recipient mice 
[23, 24]. To determine if TCRβ1 T cells can be activated to generate pathogenic cells, 
WT or TCRβ1 mice were immunized and spleens were harvested 10 days later and 
stimulated in vitro with MOG, IL-6, and IL-23 for 5 days. These cultured T cells were 
then transferred into sub-lethally irradiated TCRβ-/- mice (450 rad), and disease 
progression was monitored (Table 3-1 and Figure 3-4b). Mice that received either WT 
or TCRβ1 T cells cultured under these conditions developed rapid and severe EAE. 
Disease incidence and area under the curve were not significantly different between 
groups.  
 
Third, we directly compared retrogenic TCRβ1 mice [19], which we previously 
reported to develop severe, spontaneous EAE, and “mock” retrogenic TCRβ1 mice. For 
retrogenic mice, bone marrow from TCRβ-/- mice were transduced with MSCV-TCRβ1-
GFP viral supernatant. For “mock” retrogenic mice, bone marrow from TCRβ1 
transgenic mice was transduced with MSCV-GFP viral supernatant. The transduced bone 
marrow was injected into irradiated TCRβ-/- mice. Mock retrogenic mice had earlier onset 
of disease, but maximal severity and area under the curve were not significantly different 
(Table 3-2 and Figure 3-4c). Taken together, these data indicate that there is no intrinsic 
block to TCRβ1 T cells becoming pathogenic under the right conditions. 
 
 
TCRβ1 T Cells Differentiate and Produce Effector Cytokines 
 
In early studies, EAE was thought to be a prototypical Th1 autoimmune disease 
due to its strong association with IFN-γ. However, IFN-γ knockout mice or IFN-γ 
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Figure 3-4. TCRβ1 transgenic T cells are not intrinsically non-pathogenic 
(a) Adoptive transfer of bone marrow cells from TCRβ1 transgenic mice or (b) Activated 
CD4+ T cells from TCRβ1 transgenic and WT mice into TCRβ-/- recipients. (c) Clinical 
scoring of retrogenic and mock retrogenic TCRβ1 mice. 
 
 
 
 
Table 3-1. Summary of adoptive EAE transfer experiment 
 
 WT group  TCRβ1 group 
Measurements Mean SEM  Mean SEM 
Day of disease onset  13.0 0.8 7.8 0.5 
Area under the curve 103.0 3.3 112.6 5.8 
Mortality 5/5 N/A 3/5 N/A 
Disease incidence 5/5 N/A 5/5 N/A 
Maximum peak disease score 5.0 0.0 4.7 0.2 
 
Day of disease onset, integrated disease score (area under the curve [AUC]), mortality 
rate, disease incidence, and maximum peak disease score are listed for adoptive EAE 
transfer experiment. 
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Table 3-2. Summary of making retrogenic and mock retrogenic mice experiment 
 
 Retrogenic group  Mock retrogenic group 
Measurements Mean SEM  Mean SEM 
Day of disease onset  31.2 0.8 26.5 3.1 
Area under the curve 51.9 7.0 59.8 15.8 
Mortality 3/5 N/A 4/9 N/A 
Disease incidence 5/5 N/A 8/9 N/A 
Maximum peak disease score 4.0 0.6 3.9 0.5 
 
Day of disease onset, integrated disease score (area under the curve [AUC]), mortality 
rate, disease incidence, and maximum peak disease score are listed for adoptive EAE 
transfer experiment. 
  
 14 
neutralizing antibody treatment showed that EAE was exacerbated [25-27]. These results 
suggested that IFN-γ may also play a protective role in EAE. More recently the important 
role of Th17 cells and IL-17 in EAE has been revealed [28-30]. Cells that co-express IL-
17 and IFN-γ have also been reported to be highly pathogenic in EAE [31, 32]. If TCRβ1 
T cells do not differentiate into these cytokine-producing encephalitogenic cells (Th1, 
Th17 or Th1/Th17), TCRβ1 transgenic mice may be resistant to EAE. 
 
We then determined if TCRβ1 transgenic T cells could differentiate into cytokine-
producing cells. Because there are very few WT cells that are responsive to MOG, 2D2 
transgenic T cells were also analyzed as positive control for MOG-responsive T cells. 
2D2 transgenic mice [20] develop EAE disease when immunized with MOG peptide, 
contrasting with the TCRβ1 transgenic mice. Splenocytes from immunized TCRβ1 
transgenic mice were harvested and stimulated with MOG peptide in vitro, and cytokine 
production was characterized by Multiplex ELISA. The secreted cytokine analysis shows 
that TCRβ1 transgenic T cells produced more IFN-γ and IL-17 than WT T cells, however 
these levels were not significantly different from those seen with 2D2 transgenic T cells, 
which are fully pathogenic (Figure 3-5). TCRβ1 and 2D2 T cells both expressed higher 
levels of IL-10 than WT. Interestingly, higher levels of both IL-2 and IL-4 were observed 
in cultures with 2D2 T cells, relative to TCRβ1 transgenic T cells. Overall, this data 
indicates that TCRβ1 T cells are capable of producing the two cytokines critical for EAE 
development, IFN-γ and IL-17, upon MOG stimulation.  
 
 
TCRβ1 Transgenic T Cells Express High Levels of Exhaustion Markers 
 
 Activated T cells are regulated by costimulatory pathways, and negative signals 
may suppress autoimmune T cell function and pathogenicity [33, 34]. For example, the 
programmed death-1 (PD-1) molecule is found on activated CD4+ and CD8+ T cells, and 
ligation of the PD-1 receptor leads to diminished proliferation and IL-2 production, and 
limits inflammatory disease in EAE [35]. Besides PD-1, exhausted T cells also express 
other cell surface inhibitory molecules, such as lymphocyte activation gene 3 protein 
(LAG3) and CTLA4. Co-expression of these inhibitory surface markers is an indication 
of exhaustion. The expression level of these inhibitory surface molecules is positively 
correlated with the severity of exhaustion [33]. It is possible that activated T cells in 
TCRβ1 transgenic mice exhibit a higher expression level of these related exhaustion 
markers. Early exhaustion of MOG-reactive T cells in TCRβ1 transgenic mice may leave 
them unable to promote EAE. 
 
We harvested splenocytes from immunized WT.TCRβ1transgenic mice and 2D2 
mice, labeled them with cell trace violet, stimulated them with MOG peptide in vitro, and 
determined the expression of exhaustion markers PD-1, Lag3, CTLA4, and KLRG on 
CD4+ MOG-responsive TCRβ1 T cells. Our results show that CD4+ MOG-responsive T 
cells from TCRβ1 transgenic mice have higher PD1 expression, compared with both WT 
mice and 2D2 MOG-responsive cells (Figure 3-6). CD4+ MOG-responsive T cells in 
TCRβ1 transgenic mice also had significantly higher expression of Lag3 compared with 
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Figure 3-5. Cytokine expression profiles in MOG-stimulated TCRβ1 cultures 
TCRβ1, WT, and 2D2 mice were immunized with MOG35-55 peptide. Splenocytes from 
immunized TCRβ1, WT and 2D2 mice were isolated 10 days later and labeled with 
CellTrace Violet and cultured without or with 100 μg/ml MOG35-55 and secreted IFN-γ, 
IL-2, IL-4, IL-10, and IL-17 were measured at 72 hr by Multiplex ELISA assay. Mean 
value of each individual mouse was plotted. Data are representative of two experiments 
(*p<0.05, ***p<0.001, ****p<0.0001). 
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Figure 3-6. TCRβ1 transgenic T cells express higher levels of exhaustion markers 
TCRβ1, WT mice and 2D2 mice were immunized with MOG35-55 peptide and splenocytes 
from immunized TCRβ1 or WT or 2D2 mice were isolated 10 days later. Experiments 
were done in triplicates for individual mouse, 3 mice per each group. Splenocytes were 
labeled with CellTrace Violet and stimulated with MOG or αCD3 for 72 hr. Expression 
level of exhaustion markers (PD-1, CTLA-4, Lag-3, KLRG) on CD4+ T cells were 
determined by flow cytometry. (a) Representative histogram of MOG-responsive CD4+ T 
cells. (b) Representative histograms showing expression of exhaustion markers in MOG-
responsive CD4+ T cells (left gate in a Red line: TCRβ1 transgenic mice; blue line: WT 
mice; black line: 2D2 mice. (c) Summary data showing expression of exhaustion markers 
as MFI. (d) Summary data showing percentages of the MOG-responsive CD4+ T cells 
which is positive for exhaustion marker (PD-1, CTLA-4, Lag-3, KLRG) respectively. 
(*p<0.05, **p<0.01, ****p<0.0001). 
  
 17 
WT mice upon MOG stimulation. However, the expression level of Lag3 on MOG-
responsive T cells in TCRβ1 transgenic mice was significantly lower than 2D2 T cells. 
The flow cytometry data also showed that the expression levels of CTLA4 and KLRG 
were comparable between TCRβ1 transgenic mice, WT mice and 2D2 mice upon MOG 
stimulation. But the percentage of CD4+ MOG-responsive T cells in TCRβ1 transgenic 
mice expressing CTLA4 was significantly higher than WT and 2D2 mice. Higher 
expression level of these exhaustion-associated markers may indicate that TCRβ1 
transgenic T cells face early exhaustion. 
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CHAPTER 4.    DISCUSSION 
 
 
 Expression of public TCRβ chain, TCRβ1, was sufficient to induce spontaneous 
and severe EAE in retrogenic mice. However, our results show that TCRβ1 does not lead 
to the development of spontaneous EAE in a transgenic setting. Furthermore, TCRβ1 
mice were not susceptible to induction of active EAE. The comparison of transgenic and 
retrogenic mice has enabled us to investigate the determinants of this altered 
pathogenicity of a single TCRβ chain, and may provide insights into mechanisms of 
tolerance and disease induction in EAE. 
 
 TCRβ1 transgenic mice had percentages and numbers of CD4+ and CD8+ T cell 
comparable to WT C57BL/6 mice in the spleen and lymph node, but Foxp3+ regulatory T 
cells were significantly reduced in both number and percentage in TCRβ1 transgenic 
mice. Regulatory T cells have a well characterized role in suppression of effector CD4+ T 
cells and controlling cytokine production in MOG-induced EAE models [36, 37]. Our 
result suggests that resistance to EAE in TCRβ1 transgenic mice is not likely associated 
with increased suppression by Treg. However, this should be further investigated as these 
Tregs may have increased suppressive function. 
 
 It is also possible that other regulatory or protective cell populations are over-
represented or highly active in TCRβ1 transgenic mice. CD8+ T cells play a controversial 
role in EAE, with some studies suggesting they are pathogenic in EAE, and others 
showing them to play a suppressive role [38, 39]. Given our observation that some CD8+ 
T cells in TCRβ1 mice are MOG-responsive, this should be further investigated. 
Immunosuppressive Tr1 cells have also been reported to ameliorate EAE in mice and MS 
in humans [40]. Invariant NKT cells have also been shown to suppress EAE [41]. 
Regulatory B cells also have been reported to induce regulatory CD4+ T cell responses by 
inducing IL-10 in mice with EAE [42]. Another cell subset which responsible for 
peripheral tolerance are myeloid derived suppressor cells (MDSCs), which have been 
shown to be a new negative regulator for EAE [43]. These potential suppressive 
populations should be further characterized in the future. In addition, to analysis of 
potentially suppressive populations, there is the fundamental question of whether TCRb1 
cells are simply non-pathogenic, or protective against disease. The active immunization 
model and adoptive EAE transfer model will be useful in adoptive transfer experiments 
to address this question.  
 
 Thymocytes with high affinity for autoantigen are clonally deleted through 
negative selection. Potentially autoreactive T cells can escape thymic deletion, and be 
exported to peripheral lymphoid organs where they may induce autoimmune disease [44-
46]. We have shown here that autoreactive TCRβ1 T cells are not deleted during 
development and are indeed exported to peripheral organs. We confirmed that TCRβ1 
conferred responsiveness to self-antigen in TCRβ1 transgenic mice, and that these MOG 
responsive T cells were further expanded upon immunization. Therefore, this single 
TCRβ chain promotes reactivity to disease-associated autoantigens. 
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We were able to manipulate TCR?1 transgenic T cells in three different models to 
confer pathogenicity and promote EAE in mice. First, transfer of TCR?1 transgenic bone 
marrow was able to induce mild EAE in TCR?-deficient recipient mice. Second, 
splenocytes from TCR?1 transgenic mice were capable of inducing early and severe EAE 
in recipient mice, after culture in cytokines known to promote T cell pathogenicity in the 
MOG EAE model. Third, transduction of TCR?1 bone marrow with MSCV empty vector 
induced disease and mimicked the results initially observed in the retrogenic system. 
These three models all suggest that TCR?1 transgenic T cells have the potential to 
become pathogenic, and there is no intrinsic blockade for TCR?1 to confer pathogenicity 
in mice. This implies that the inability to induce EAE in these mice is a product of some 
tolerance generated in transgenic host environment. 
 
 We then proposed that TCRβ1 transgenic T cells may not be able to produce 
cytokines which are essential for pathogenesis. To test this hypothesis, multiplex assay 
was performed. The multiplex ELISA data showed that TCRβ1 transgenic T cells 
secreted significantly more IFN-γ compared with WT mice. IFN-γ has been reported to 
ameliorate EAE by limiting myelin lipid peroxidation [30]. Thus the high concentration 
of IFN-γ produced by TCRβ1 transgenic T cells may possibly protect the mice from 
disease development. Future experiments using IFN-γ neutralizing antibodies would be 
useful to further investigate this. 
 
 Another hypothesis is that MOG-reactive T cells in TCRβ1 transgenic mice face 
early exhaustion. In order to test this, we determined the expression level of exhaustion 
markers of MOG-reactive T cells. The expression of PD-1 and Lag3 was significantly 
higher in MOG-reactive T cells in TCRβ1 transgenic mice in comparison with WT mice 
and 2D2 mice. Though the expression level of CTLA4 was comparable between WT 
mice and TCRβ1 mice, the percentage of CTLA4+ MOG-reactive T cells were 
significantly higher in TCRβ1 transgenic mice than WT mice. This indicates that MOG-
reactive T cells in TCRβ1 transgenic mice may be more prone to early exhaustion upon 
stimulation with MOG35-55. It would be useful to treat mice with anti-PD-1 antibodies to 
resolve the effects of exhaustion on TCRβ1 T cells during EAE. 
 
 One other possibility we have not addressed is whether the high affinity of 
TCRβ1 chain to MOG35-55 leads to the protection against EAE in mice. We previously 
isolated CNS-infiltrating TCRβ1+ TCRs from WT mice and identified TCRα sequences 
from them. These were paired with TCRβ1 in retroviral constructs. TCR 342α showed 
the highest level of MOG responsiveness in vitro [19]. We have generated TCR342α 
transgenic mice, and crossed them with TCRβ1 transgenic mice. Similar to TCRβ1 
transgenic mice, the TCRβ1/TCR342α transgenic mice do not develop spontaneous EAE 
and are resistant to active immunization with MOG35-55. There are several reasons why 
the high affinity of TCRβ1 and the TCRβ1/TCR342α pair may inhibit the development of 
autoimmunity. T cells with high affinity TCR could lead to early exhaustion or apoptosis. 
Autoreactive T cells clones bearing high affinity TCRs are held in the periphery by 
functional inactivation. T cells with high affinity TCRs have also been reported to 
preferentially upregulate the inhibitory mediators IL-10, CTLA4, TIGIT, and GITR [47-
49]. Lower affinity TCR has been reported to be capable of passing negative selection 
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and may have a greater potential to cause an experimental autoimmune disease [50]. 
TCRβ1 has high affinity for MOG antigen which could possibly inhibits development of 
EAE in transgenic mice. Further experiments also need to be done to determine if the 
high affinity of TCRβ1 for MOG-IAb leads to co-receptor independent T cell activation, 
which could explain why we see CD8+ transgenic T cells responding to MOG 
stimulation. Such co-receptor independent cells may be non-pathogenic or have 
protective functions. Experiments may include defining effector responses of T cells from 
TCRβ1 to MOG-derived altered peptide ligands (APLs) that have lower TCR affinity in 
vitro and in vivo. For instance, immunization of TCRβ1 transgenic mice with lower 
affinity MOG APLs could be used to determine if priming with lower affinity antigen 
will induce susceptibility to EAE.  
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